NCT04715048

Split-Face Study Comparing Botox and Jeuveau in Treating Glabellar Lines

Split-Face Study Comparing OnabotulinumtoxinA (Botox) and PrabotulinumtoxinA (Jeuveau) in Treating Glabellar Lines

• Status: Unknown
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: University of Southern California · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to compare the efficacy and side effects of Botox and Jeuveau for glabellar lines.

Detailed description

After being informed about the study and potential risks, all patients given consent will receive Botox on one side of their face and Jueveau on the other. A random number generator will generate a list of 20 combinations of "1,2" or "2,1". "1,2" means the Botox (onabotulinumtoxin A) will be placed on the right side and "2,1" means that the Botox will be placed on the left. The other side will be injected with PrabotulinumtoxinA. 8-10 units will be injected into the designated glabella in 3 sites.

Conditions

• Glabellar Frown Lines

Interventions

Type	Name	Description
DRUG	PrabotulinumtoxinA	Glabellar line correction
DRUG	Onabotulinum toxin A	Glabellar line correction

Timeline

• Start date: 2021-01-01
• Primary completion: 2025-05-01
• Completion: 2025-06-01
• First posted: 2021-01-20
• Last updated: 2023-12-14

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study